Ipsen's Cabometyx (cabozantinib- as monothx) Receives EU Approval for the Treatment of 2L Advance HCC
Shots:
- The approval is based on P-III CELESTIAL trial result assessing Cabometyx (60 mg qd) vs PBO in 760 patients in ratio (2:1) with advanced HCC receiving 2L treatment & treated with sorafenib
- The P-III CELESTIAL study demonstrated meeting of all 1EPs & 2Eps of the trial- with safety and efficacy & shown improvements in overall survival rates
- Cabometyx is a tyrosine kinase inhibitor- indicated and will be available in EU including Norway & Iceland. In 2016- Ipsen acquired exclusive commercialization rights of Cabometyx (ex. In the US & Japan) form Exelixis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
